Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ensulizole is a water-soluble small molecule sunscreen agent primarily used as a UVB filter in cosmetic and sunscreen products. It absorbs strongly at UV-B wavelengths (290–340 nm), providing protection against sunburn and DNA damage induced by UVB radiation. Ensulizole offers minimal UVA protection and is often combined with other agents like avobenzone, titanium dioxide, or zinc oxide for broader spectrum coverage. Its water solubility allows for lighter-feeling formulations compared to oil-based filters. Mechanistically, ensulizole protects skin by absorbing UVB photons; however, upon photoexcitation it can also generate reactive oxygen species and induce DNA strand breaks via type I and II photosensitization mechanisms following exposure to UVA or UVB light[2][6][7]. Ensulizole is approved by regulatory agencies such as the FDA (United States), European Commission (EU), Australia, Canada, and Japan for use in over-the-counter sunscreen products[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ensulizole.